Progress in Single-cell RNA Sequencing of Lung Adenocarcinoma.
10.3779/j.issn.1009-3419.2021.102.19
- Author:
Yichu LIN
1
;
Donglai CHEN
2
;
Qifeng DING
1
;
Xuejuan ZHU
1
;
Rongying ZHU
1
;
Yongbing CHEN
1
Author Information
1. Department of Thoracic Surgery, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
2. Department of
Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China.
- Publication Type:Journal Article
- Keywords:
Drug resistance;
Lung neoplasms;
Progression;
Single-cell sequencing
- From:
Chinese Journal of Lung Cancer
2021;24(6):434-440
- CountryChina
- Language:Chinese
-
Abstract:
Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer and one of the main causes of cancer-related deaths. In the past decade, with the widespread use of computed tomography (CT) in routine screening for lung cancer, the incidence of LUAD presenting as small pulmonary nodules radiologically, has increased remarkably. The mechanisms of the occurrence and progression of LUADs are complex, and the prognoses of patients with LUAD vary significantly. Although significant progress has been made in targeted therapy and immunotherapy for LUADs in recent years, the drug resistance of tumor cells has not been effectively overcome, which limits the benefits of patients. With the accomplishment of the Human Genome Project, sequencing-based genomic and transcriptomics have come into the field of clinical and scientific researches. Single-cell sequencing, as a new type of sequencing method that has captured increasing attention recently, can perform specific analysis of cell populations at single-cell level, which can reveal the unique changes of each cell type. Single-cell sequencing can also provide accurate assessment on heterogeneous stromal cells and cancer cells, which is helpful to reveal the complexity of molecular compositions and differences between non- and malignant tissues. To sum up, it is an urgent need for clinicians and basic scientists to deeply understand the pathogenesis and development of LUAD, the heterogeneity of tumor microenvironment (TME) and the mechanism of drug resistance formation through single-cell sequencing, so as to discover new therapeutic targets. In this paper, we reviewed and summarized the application and progress in single-cell sequencing of LUADs.
.
